Document is current
Any future updates will be listed below
-
Authors
Grebinoski, Stephanie
Gocher-Demske, Angela M.
Vignali, Dario A. A. https://orcid.org/0000-0002-2771-5992
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35 CA263850, CA247004, CA082084)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (P01 AI108545, R01 AI144422, R01 AI129893, AI147638, AI089443)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK089125)
- License Information
-
More Information
Article History
First Online: 21 February 2022
Competing interests
: D.A.A.V. declares competing financial interests and has submitted patents covering LAG3 that are licensed or pending and is entitled to a share in net income generated from licensing of these patent rights for commercial development. D.A.A.V.: cofounder and stock holder of Novasenta, Potenza, Tizona, Trishula; stock holder of Oncorus, Werewolf, Apeximmune; patents licensed and royalties for Astellas, BMS, Novasenta; scientific advisory board member of Tizona, Werewolf, F-Star, Bicara, Apeximmune; consultant for Astellas, BMS, Almirall, Incyte, G1 Therapeutics; research funding from BMS, Astellas and Novasenta.
